title: [Parallel pharmacological correction of myocardial dysfunction, cognitive and psychopathological disordres in patients with congestive heart failure].
abstract: Was examined 92 patients with congestive heart failure III-IV FC with fraction of emission left ventricle < 45% against coronary artery disease. Patients of control group received basic therapy (according to recommendations of the Ukrainian society of cardiology), the 1 group--in addition received a preparation of Vazonat within 15 days intravenously in a dose of 1000 mg a day further are out-patient within 1 month on 250 mg 3 times per os; the 2 group--under the same scheme a preparation of Vazonat and a day tranquilizer of Adapto in a dose of 500 mg twice a day throughout all term of supervision. It is established that addition of Vazonat to basic treatment leads to additional effect concerning improvement of indicators cardio-hemodynamic, to improvement congestive functions. Joint appointment of preparations of Vazonat and Adaptol against basic treatment leads to more expressed improvement congestive functions, to progressive reduction of degree of trouble, depression.
authors.forename: N Ia
authors.initials: NIa
authors.lastname: Dotsenko
authors.forename: S S
authors.initials: SS
authors.lastname: Boev
authors.forename: I A
authors.initials: IA
authors.lastname: Shekhunova
authors.forename: V O
authors.initials: VO
authors.lastname: Dedova
mesh_terms: D000368:Aged; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001736:Biureas / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects; D004359:Drug Therapy, Combination; D004452:Echocardiography; D005080:Exercise Test; D006333:Heart Failure / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology / Q000523:psychology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008763:Methylhydrazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D009206:Myocardium / Q000473:pathology; D009483:Neuropsychological Tests; D011602:Psychophysiologic Disorders / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D014151:Anti-Anxiety Agents; D001736:Biureas; D002317:Cardiovascular Agents; D008763:Methylhydrazines; C015979:mebikar; C050147:3-(2,2,2-trimethylhydrazine)propionate